SG11202003300WA - Compositions and methods for treatment of fibrosis - Google Patents
Compositions and methods for treatment of fibrosisInfo
- Publication number
- SG11202003300WA SG11202003300WA SG11202003300WA SG11202003300WA SG11202003300WA SG 11202003300W A SG11202003300W A SG 11202003300WA SG 11202003300W A SG11202003300W A SG 11202003300WA SG 11202003300W A SG11202003300W A SG 11202003300WA SG 11202003300W A SG11202003300W A SG 11202003300WA
- Authority
- SG
- Singapore
- Prior art keywords
- fibrosis
- compositions
- treatment
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762570847P | 2017-10-11 | 2017-10-11 | |
| PCT/US2018/055521 WO2019075277A1 (en) | 2017-10-11 | 2018-10-11 | COMPOSITIONS AND METHODS FOR TREATING FIBROSIS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202003300WA true SG11202003300WA (en) | 2020-05-28 |
Family
ID=66101109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202003300WA SG11202003300WA (en) | 2017-10-11 | 2018-10-11 | Compositions and methods for treatment of fibrosis |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12544394B2 (https=) |
| EP (1) | EP3694517A4 (https=) |
| JP (1) | JP7379348B2 (https=) |
| KR (1) | KR20200068692A (https=) |
| CN (1) | CN111278441A (https=) |
| AU (1) | AU2018347527B2 (https=) |
| CA (1) | CA3084359A1 (https=) |
| IL (1) | IL273850B1 (https=) |
| MX (1) | MX2020003718A (https=) |
| SG (1) | SG11202003300WA (https=) |
| WO (1) | WO2019075277A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY210343A (en) * | 2020-06-04 | 2025-09-12 | Hovid Berhad | Composition for normalisation of fatty liver and method for producing the same |
| EP4274566A4 (en) * | 2021-01-06 | 2024-10-30 | The Trustees of Indiana University | TOCOTRIENOL COMPOSITIONS AND METHODS FOR TREATING NONALCOHOLIC STEATOHEPATITIS |
| CN112587649A (zh) * | 2021-01-19 | 2021-04-02 | 中日友好医院(中日友好临床医学研究所) | 一种三肽化合物及其铜离子螯合物在预防和治疗矽肺中的应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1171047A (en) * | 1915-11-10 | 1916-02-08 | John Hornagy | Car-door fastener. |
| US2282236A (en) * | 1940-06-19 | 1942-05-05 | Bay State Optical Co | Eyeglass construction |
| US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
| US5284835A (en) * | 1992-07-31 | 1994-02-08 | Lieber Charles S | Use of dilinoleoylphosphatidylcholine (DLPC) for treatment and prevention of cirrhosis and fibrosis in the liver |
| AR002009A1 (es) * | 1994-12-22 | 1998-01-07 | Astra Ab | Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco. |
| CA2181390C (en) * | 1995-07-18 | 2001-04-24 | Pankaj Modi | Phospholipid formulations |
| WO1997006784A1 (en) | 1995-08-15 | 1997-02-27 | Universite Libre De Bruxelles | Liposomes preparation method and plant |
| CA2282236A1 (en) * | 1998-11-06 | 2000-05-06 | Peter Stys | The use of excitatory amino acid transporter inhibitors to protect against cns white matter injury |
| US20040146516A1 (en) * | 1999-06-17 | 2004-07-29 | Utah Ventures Ii L.P. | Lumen-exposed molecules and methods for targeted delivery |
| CN1518987A (zh) * | 2000-06-02 | 2004-08-11 | 大连万友贸易有限公司 | 多聚不饱和磷脂酰胆碱的新用途 |
| US20060115523A1 (en) * | 2004-12-01 | 2006-06-01 | Konduri Kameswari S | Sterically stabilized liposome and triamcinolone composition for treating the respiratory tract of a mammal |
| US20080107723A1 (en) * | 2006-09-28 | 2008-05-08 | Perkins Walter R | Methods of Treating Pulmonary Distress |
| JP5080779B2 (ja) | 2006-10-25 | 2012-11-21 | テルモ株式会社 | リポソーム製剤の製造方法 |
| WO2011009119A2 (en) | 2009-07-17 | 2011-01-20 | The Regents Of The University Of Michigan | Compositions and methods for diagnosing and treating fibrotic disorders |
| CA3102008A1 (en) | 2010-06-02 | 2011-12-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods directed to treating liver fibrosis |
| US20160015656A2 (en) * | 2010-08-05 | 2016-01-21 | Nitto Denko Corporation | Composition for regenerating normal tissue from fibrotic tissue |
| US9585930B2 (en) | 2011-03-20 | 2017-03-07 | Trustees Of Boston University | Therapeutic agent for emphysema and COPD |
| CN102631330B (zh) * | 2012-04-19 | 2013-05-29 | 海南美大制药有限公司 | 一种兰索拉唑囊泡型磷脂凝胶缓释固体制剂 |
| HK1207977A1 (en) * | 2012-04-25 | 2016-02-19 | Trustees Of Tufts College | Silk microspheres and methods for surface lubrication |
| EP2874605A1 (en) | 2012-07-18 | 2015-05-27 | Onyx Therapeutics, Inc. | Liposomal compositions of epoxyketone-based proteasome inhibitors |
| KR20160125352A (ko) * | 2013-12-20 | 2016-10-31 | 이센셜 파마수티컬스 엘엘씨 | 세포 배양용 배지 |
| CN103816118A (zh) * | 2014-02-14 | 2014-05-28 | 西藏海思科药业集团股份有限公司 | 一种多烯磷脂酰胆碱注射用组合物及其制备方法 |
| KR20170107256A (ko) | 2016-03-15 | 2017-09-25 | 이진희 | 미백 화장료 조성물 |
| CN105997854B (zh) * | 2016-06-14 | 2018-11-27 | 成都天台山制药有限公司 | 多烯磷脂酰胆碱注射液组合物和制法 |
| CN106310220A (zh) | 2016-08-17 | 2017-01-11 | 浙江中医药大学 | 一种包封鳖甲肽的rgd‑ssl脂质体及其制备方法 |
-
2018
- 2018-10-11 JP JP2020542041A patent/JP7379348B2/ja active Active
- 2018-10-11 MX MX2020003718A patent/MX2020003718A/es unknown
- 2018-10-11 EP EP18867017.8A patent/EP3694517A4/en active Pending
- 2018-10-11 AU AU2018347527A patent/AU2018347527B2/en active Active
- 2018-10-11 CA CA3084359A patent/CA3084359A1/en active Pending
- 2018-10-11 US US16/755,245 patent/US12544394B2/en active Active
- 2018-10-11 CN CN201880070455.7A patent/CN111278441A/zh active Pending
- 2018-10-11 KR KR1020207012908A patent/KR20200068692A/ko active Pending
- 2018-10-11 SG SG11202003300WA patent/SG11202003300WA/en unknown
- 2018-10-11 WO PCT/US2018/055521 patent/WO2019075277A1/en not_active Ceased
-
2020
- 2020-04-06 IL IL273850A patent/IL273850B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20200246361A1 (en) | 2020-08-06 |
| IL273850B1 (en) | 2026-01-01 |
| EP3694517A4 (en) | 2021-07-14 |
| CN111278441A (zh) | 2020-06-12 |
| IL273850A (en) | 2020-05-31 |
| AU2018347527A1 (en) | 2020-04-23 |
| JP2021502404A (ja) | 2021-01-28 |
| KR20200068692A (ko) | 2020-06-15 |
| WO2019075277A1 (en) | 2019-04-18 |
| EP3694517A1 (en) | 2020-08-19 |
| US12544394B2 (en) | 2026-02-10 |
| CA3084359A1 (en) | 2019-04-18 |
| BR112020007083A2 (pt) | 2020-09-24 |
| MX2020003718A (es) | 2020-10-05 |
| JP7379348B2 (ja) | 2023-11-14 |
| AU2018347527B2 (en) | 2024-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274276A (en) | CASZ preparations and methods of use | |
| GB2582100B (en) | CAS12C Compositions and methods of use | |
| ZA201906169B (en) | Synthekine compositions and methods of use | |
| SG11202004680UA (en) | Cellular compositions and methods of treatment i | |
| IL275182A (en) | Preparations and methods for the treatment of metabolic conditions | |
| IL269590A (en) | Methods and compositions for reducing immunogenicity | |
| ZA201804380B (en) | Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same | |
| ZA201607878B (en) | Compositions and methods of treating cardiac fibrosis with ifetroban | |
| EP3253211A4 (en) | Compositions and methods for treatment of edema | |
| SG11201803284YA (en) | Novel method of use and compositions | |
| ZA201802376B (en) | Compositions and methods for treatment of homocystinuria | |
| IL273850A (en) | Preparations and methods for the treatment of leprosy | |
| GB201511799D0 (en) | Composition and methods of treatment | |
| ZA201706985B (en) | Compositions for the treatment of fibrosis and fibrosis-related conditions | |
| GB201621737D0 (en) | Compositions and methods of treatment | |
| SG11202000612TA (en) | Methods and compositions for the treatment of melanoma | |
| DK3359209T3 (en) | Compositions and methods for treatment of bone defects | |
| GB201605127D0 (en) | Composition and methods of treatment | |
| GB201810923D0 (en) | Compositions and method of treatment | |
| IL265242B (en) | Compounds for the treatment of hypertension and/or fibrosis | |
| IL262547A (en) | Methods and compositions for treatment of rett syndrome | |
| GB201710491D0 (en) | Composition and methods of treatment | |
| HK40036545A (en) | Compositions and methods for treatment of fibrosis | |
| ZA202004110B (en) | Compositions and methods for the treatment of metabolic conditions | |
| GB201810925D0 (en) | Compositions and methods of treatment |